Leading the
small molecule
Revolution

We combine the power of chemoproteomics and covalent chemistry to forge life-changing connections between precision therapeutics and previously undrugged drivers of disease.

Leading
the small
molecule
Revolution

We combine the power of chemoproteomics and covalent chemistry to forge life-changing connections between precision therapeutics and previously undrugged drivers of disease.

We are bringing more disease-causing targets within the reach of small molecule therapeutics to transform care for patients with devastating diseases not addressed by current therapies.

Committed to patient impact


Our drug discovery engine has yielded multiple novel drug candidates that are being evaluated in clinical trials.

learn about our Programs

Transforming drug discovery


Chemoproteomics provides the lens for an expansive view of the human proteome that enables us to find novel ways to develop small molecules with therapeutic potential. 

learn about our Platform

We are driven by scientific curiosity, creativity,
and an urgent drive for innovation

Vividion’s unique chemoproteomics platform allows us to identify and pursue novel strategies to target pathways that contribute to human disease. One of the most rewarding aspects of this drug discovery approach is the ability to explore hypotheses related to our therapeutic strategies, in hopes of finding the optimal ways to bring our treatments to patients.”

-Joseph Klebba, Ph.D., Associate Director, Oncology Early Discovery Sciences

Join Our Team

Joseph Klebba

Associate Director, Oncology Early Discovery Sciences

Our latest advances

October 8, 2024

Vividion Therapeutics Appoints Frank Poschen to Board of Directors

Press Release

July 23, 2024

Vividion Therapeutics to Expand with New Global Research and Development Center

Press Release

April 25, 2024

Vividion Therapeutics and Roche Jointly Publish Landmark Nature Paper on Clinical-Stage Covalent Allosteric Inhibitor of Werner Helicase (WRN)

Press Release